paclitaxel-coated balloon

Clinical Trial Update

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

12/09/2019

Vascular Disease Management talks with IMPERIAL trial co-principal investigator William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania.

Vascular Disease Management...

12/09/2019

Vascular Disease Management

Rapid Communication

Lower Paclitaxel Dose, Smaller Delivery Platform: 12-Month Data From the RANGER SFA II Trial

11/12/2019

Ravish Sachar , MD, FACC;

Vascular Disease Management talks with Ravish Sachar, MD, FACC, University of North Carolina - Rex Hospital Physician-in-Chief for Heart and Vascular Services, and Principal Investigator of the RANGER II SFA trial.

Vascular Disease Management...

11/12/2019

Vascular Disease Management

EP Tips & Techniques

Drug-Coated vs Uncoated Percutaneous Transluminal Angioplasty in Infrapopliteal Arteries: Six-Month Results of the Lutonix BTK Trial

07/23/2019

Jim Brooks ;

Jim Camden ;

Jihad A. Mustapha , MD, FACC, FSCAI;

Marianne Brodmann , MD;

Fadi Saab , MD, FACC, FSCAI;

Michael R. Jaff , MD, DO;

We hypothesized that a drug-coated balloon could improve treatment efficacy while maintaining safety when compared with percutaneous transluminal angioplasty for the treatment of atherosclerotic infrapopliteal arterial lesions.

We hypothesized that a...

07/23/2019

Journal of Invasive Cardiology

FDA Panel

Current Antiproliferative Considerations: The Eluvia Stent

06/25/2019

Steve Henao , MD, FACS, FACC;

Steve Henao, MD, FACS, FACC, from New Mexico Heart Institute, Albuquerque, New Mexico, discusses the use of paclitaxel-coated devices to treat PAD.

Steve Henao, MD, FACS, FACC,...

06/25/2019

Vascular Disease Management

FDA Panel

Accepting the Risk of Treatment with Drug-Coated Balloons

06/22/2019

Frank J. Veith , MD;

VDM talks with Frank J. Veith, MD, Professor of Surgery, New York University-Langone Medical Center and The Cleveland Clinic Lerner College of Medicine; The William J. von Liebig Chair in Vascular Surgery; Cleveland, Ohio and New York, New...

VDM talks with Frank J. Veith,...

06/22/2019

Vascular Disease Management

Editor's Corner

A Potential Danger Signal Associated With Paclitaxel-Eluting Devices

01/21/2019

Craig M. Walker , MD, FACC, FACP, FSCAI, FCCP;

Dr. Walker comments on a hotly debated meta-analysis by Katsanos and colleagues on the risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg.

Dr. Walker comments on a hotly...

01/21/2019

Vascular Disease Management

Original Contribution

Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease

06/30/2016

Sanjum S. Sethi , MD, MPH;

Michael S. Lee , MD, DPM, FACFAS, FACC, FSCAI;

A review of paclitaxel-coated balloons as an emerging therapeutic option for the invasive management of infrainguinal peripheral artery disease.

A review of paclitaxel-coated...

06/30/2016

Journal of Invasive Cardiology